US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

VERIDIEN CLIMATE ACTION ETF

18.61

+0.0000

Volume:- -

Turnover:- -

Market Cap:4.09M

PE:- -

High:18.61

Open:18.61

Low:18.61

Close:18.61

Loading ...

Overview Company News Filings

Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer

Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD

Proteomics Opens Certified Clinical Laboratory in California; Shares Fall 8%

MT Newswires Live

Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer

Labcorp Announces Clinical Availability of Liquid Biopsy Test to Guide Personalized Treatment Plans for Patients with Advanced Solid Tumors

Undiscovered Gems In The US Featuring Anbio Biotechnology And 2 Other Small Caps

Simply Wall St.

Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025

GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System

NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma

Natera Announces National Commercial Coverage for its Fetal RhD NIPT

Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer

Natera to Present New Data at the 2025 ASCO GI Symposium

Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year

Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CLIA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CLIA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLIA\",,,,,undefined,":{"symbol":"CLIA","market":"US","secType":"STK","nameCN":"VERIDIEN CLIMATE ACTION ETF","latestPrice":18.61,"timestamp":1742587200000,"preClose":18.61,"halted":0,"volume":0,"delay":0,"changeRate":0,"change":0,"floatShares":220000,"shares":220000,"lyrEps":0,"amount":0,"amplitude":0,"dividePrice":0.08023,"prevYearClose":20.7542},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLIA\",,,,,undefined,":{"symbol":"CLIA","floatShares":220000,"roa":"--","roe":"--","lyrEps":0,"shares":220000,"dividePrice":0.08023,"high":18.61,"amplitude":0,"preClose":18.61,"low":18.61,"week52Low":16.48,"pbRate":"--","week52High":21.28,"institutionHeld":0,"latestPrice":18.61,"eps":0,"divideRate":0.004311,"volume":0,"delay":0,"ttmEps":0,"open":18.61,"prevYearClose":20.7542},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLIA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-08-19","symbol":"CLIA","reason":null,"defaultRemindTime":1724074200000,"announcedDate":"2024-08-05","type":"delisting","dateTimestamp":1724040000000},{"date":"2023-12-26","symbol":"CLIA","amount":0.080227,"announcedDate":"2023-12-22","type":"dividend","market":"US","newRecordDate":"2023-12-27","defaultRemindTime":1703601000000,"name":"VERIDIEN CLIMATE ACTION ETF","recordDate":"2023-12-28","payableDate":"2023-12-27","currency":"USD","dateTimestamp":1703566800000,"payDate":"2023-12-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLIA\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-26","recordDate":"2023-12-27","paymentDate":"2023-12-28","value":0.080227,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLIA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CLIA\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2518322658","title":"Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2518322658","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518322658?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:00","pubTimestamp":1741608000,"startTime":"0","endTime":"0","summary":"HEROES is Natera’s first clinical trial using Signatera to guide de-escalation of therapy in patients with metastatic HER2+ breast cancer. Approximately 170 patients are expected to enroll in up to 35 sites in France. Human epidermal growth factor receptor 2  is a type of protein found in cancer cells that can cause rapid cancer growth when higher than normal levels are present. Between 15%-20% of breast tumors are HER2+. Current standard-of-care  recommendations for maintenance treatment include the use of anti-HER2 therapies, which for many patients means remaining on the drug for life.\"We are excited to see the first patients enrolled in the HEROES clinical trial,\" said Angel Rodriguez, M.D., senior medical director of oncology at Natera. \"Safely discontinuing treatment has been a long-lasting dile","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-announces-enrollment-first-patients-120000446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4213","CLIA","LU0012050646.USD","LU1988902786.USD","LU2065170008.USD","LU2324357040.USD","LU2065169927.USD","LU0053671581.USD","LU2065171311.SGD","LU2065171402.SGD","LU2065731478.USD","LU0963586101.USD","BK4139","LU1064131342.USD","NTRA","SOC","LU2264538146.SGD","LU0106261612.USD"],"gpt_icon":0},{"id":"2517157843","title":"Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517157843","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517157843?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:05","pubTimestamp":1741266300,"startTime":"0","endTime":"0","summary":"-- The Simple, No-cost Test Can Detect Granulocyte-Macrophage Colony Stimulating Factor  Autoantibodies in the Blood with Only a Finger Prick --. LANGHORNE, Pa., March 06, 2025----Savara Inc.  , a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot  Test in the U.S., an evolution of the first serum-based assay the Company launched. The DBS test helps obtain a diagnosis of aPAP, a rare autoimmune lung disease caused by antibodies targeting GM-CSF, with only a finger-prick blood sample.Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli  of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granuloc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-announces-u-launch-apap-130500207.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4555","BK4139","LU0320765489.SGD","LU1201861165.SGD","LU0345770308.USD","LU0162691827.USD","LU0130518102.USD","BK4099","BK4574","LU1201861249.SGD","BK4561","LU0072461881.USD","LU0345770993.USD","LU0980610538.SGD","LU0648001328.SGD","BK4559","BK4566","LU0130103400.USD","LU0130517989.USD","CLIA","LU0477156953.USD","DBS","LU0211331839.USD","GM","BK4516","BK4585","LU0070302665.USD","LU0477156797.USD","LU0006061336.USD","SVRA","BK4596","LU0208291251.USD","LU0130102774.USD","LU0648000940.SGD","BK4588"],"gpt_icon":0},{"id":"2516867846","title":"Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD","url":"https://stock-news.laohu8.com/highlight/detail?id=2516867846","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516867846?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:00","pubTimestamp":1741089600,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, March 04, 2025----Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that the U.S. Patent and Trademark Office has issued Natera a new patent related to testing of single nucleotide variants in circulating-tumor DNA . This builds on Natera’s extensive intellectual property estate, including a strong portfolio of molecular residual disease testing  patents for whole exome and whole genome sequencing.U.S. patent No. 12,203,142 relates to certain methods of preparation useful for tumor-informed ctDNA monitoring using whole exome or whole genome sequencing. The patent describes various modes of target enrichment in the plasma, including both multiplex polymerase chain reaction PCR and capture by hybridization.Natera has more than 110 patents relating to cell-free DNA analysis for oncology testing, including 23 patents obtained in 2024.Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com Media: Lesley Bogdanow","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-expands-intellectual-property-portfolio-120000592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065171402.SGD","LU1064131342.USD","NTRA","LU2065171311.SGD","LU2065731478.USD","LU2065170008.USD","LU2264538146.SGD","LU0053671581.USD","LU0012050646.USD","LU2324357040.USD","CLIA","LU2065169927.USD","LU1988902786.USD","BK4139","LU0963586101.USD","LU0106261612.USD"],"gpt_icon":0},{"id":"2514393082","title":"Proteomics Opens Certified Clinical Laboratory in California; Shares Fall 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514393082","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514393082?lang=en_us&edition=fundamental","pubTime":"2025-02-28 12:18","pubTimestamp":1740716328,"startTime":"0","endTime":"0","summary":"Proteomics International Laboratories  has opened a clinical laboratory improvement amendments  certified reference laboratory in Irvine, California, according to a Friday filing with the Australian bourse.The company has secured both a California State License and the CLIA certification, allowing it to operate as a certified clinical laboratory within the US, the filing said.The laboratory will initially offer the PromarkerD test, which predicts diabetes-related chronic kidney disease , and plans to expand with tests for esophageal cancer and endometriosis, the filing added.The launch of PromarkerD, shown to predict DKD up to four years in advance, is expected in the second quarter, the company said.The laboratory is designed for scalability, allowing Proteomics International to introduce additional diagnostic tests efficiently in the US market, the company added.Shares of the company fell 8% in recent Friday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7048","CLIA","PIQ.AU","BK7508"],"gpt_icon":0},{"id":"2514606230","title":"Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2514606230","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514606230?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:00","pubTimestamp":1740481200,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, February 25, 2025----Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that its Signatera test has met coverage requirements from the Centers for Medicare & Medicaid Services’  Molecular Diagnostics Services Program  for patients with non-small cell lung cancer . This coverage applies to patients with stage I-III NSCLC with resectable or unresectable disease in the surveillance setting. It expands upon preexisting Medicare coverage of Signatera for monitoring of immunotherapy, a common form of treatment for NSCLC in both the adjuvant and metastatic settings.Signatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with cancer. Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard of care tools, and help opt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-announces-medicare-coverage-signatera-110000094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU2637428348.USD","LU2065170008.USD","CMS","LU0053671581.USD","LU1064131342.USD","BK4208","LU1988902786.USD","LU1894683264.USD","NTRA","BK4139","LU2065169927.USD","LU1894683348.USD","LU0963586101.USD","BK4588","CLIA","LU2346227817.USD","LU2065171311.SGD","LU2264538146.SGD","LU0106261612.USD","LU2065731478.USD","LU2065171402.SGD","LU0012050646.USD"],"gpt_icon":0},{"id":"2513726337","title":"Labcorp Announces Clinical Availability of Liquid Biopsy Test to Guide Personalized Treatment Plans for Patients with Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2513726337","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513726337?lang=en_us&edition=fundamental","pubTime":"2025-02-24 20:32","pubTimestamp":1740400320,"startTime":"0","endTime":"0","summary":"Labcorp Plasma CompleteTM offers oncologists a highly sensitive and specific genomic profiling solution from a simple blood draw. BURLINGTON, N.C., Feb. 24, 2025 /PRNewswire/ -- Labcorp , a global leader of innovative and comprehensive laboratory services, announced today the clinical availability of Labcorp Plasma CompleteTM, a circulating tumor DNA -based comprehensive genomic profiling solution for patients with advanced solid tumors. The liquid biopsy test enables oncologists to perform comprehensive genomic profiling to inform personalized treatment decisions – all from a simple blood draw.Rigorous validation studies published in the Journal of Molecular Diagnostics confirmed the test's clinical accuracy and reliability. The test offers a reportable range with a variant allele frequency as low as 0.1% and a specificity greater than 99.99%, enabling the precise detection of tumor-specific biomarkers associated with disease progression and therapy resistance. This level of variant d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/labcorp-announces-clinical-availability-liquid-123200458.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/labcorp-announces-clinical-availability-liquid-123200458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1992135399.USD","BK4550","LU0950375773.USD","LU2322448791.USD","IE00B7SZL793.SGD","LU2106854487.HKD","LU2506951875.HKD","LU1923622291.USD","LU2506952170.USD","BK4196","BK4020","IE00B775SV38.USD","LU2506952097.USD","LU0354030438.USD","LU0823417653.USD","IE00B19Z4B17.USD","LU2023250504.SGD","LU0354030511.USD","LU2272731782.SGD","IE00B66KJ199.SGD","LU2506951958.HKD","LU1974910355.USD","LU2272731865.HKD","LU2322448957.HKD","LU1059921491.USD","IE00B3S45H60.SGD","LU2065171311.SGD","LU1917777945.USD","LU2065170008.USD","BK4588","LU2247934214.USD","LU2065171402.SGD","LU0823417737.USD","LU1992135472.HKD","LU2125909759.SGD","MSI","BK4157","BK4585","LU2065169927.USD","LU2125909916.SGD","LU2023250843.SGD","IE0031619046.USD","IE0034235188.USD","LU2272731600.USD","LU2473716301.USD","LH","LU0006061336.USD","AEIS","CLIA"],"gpt_icon":0},{"id":"2513500612","title":"Undiscovered Gems In The US Featuring Anbio Biotechnology And 2 Other Small Caps","url":"https://stock-news.laohu8.com/highlight/detail?id=2513500612","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513500612?lang=en_us&edition=fundamental","pubTime":"2025-02-21 18:02","pubTimestamp":1740132121,"startTime":"0","endTime":"0","summary":"The United States market has remained flat over the past week but has shown a robust 21% increase over the last year, with earnings projected to grow by 14% annually. In this dynamic environment, identifying small-cap stocks like Anbio Biotechnology that possess strong growth potential and innovative capabilities can offer intriguing opportunities for investors seeking to uncover lesser-known gems.Top 10 Undiscovered Gems With Strong Fundamentals In The United States. Get an in-depth perspective on Anbio Biotechnology's performance by reading our health report here.Operations: DRDGOLD generates revenue primarily from its Ergo and FWGR operations, with Ergo contributing ZAR 5.05 billion and FWGR adding ZAR 2.02 billion. The company's financial performance is influenced by these segments, reflecting its focus on gold extraction from surface mine tailings in South Africa.DRDGOLD, a notable player in the mining sector, showcases impressive financial stri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/undiscovered-gems-us-featuring-anbio-100201534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NPB","CLIA","NNNN","DRD","BK4017"],"gpt_icon":1},{"id":"2512175165","title":"Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2512175165","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512175165?lang=en_us&edition=fundamental","pubTime":"2025-02-18 22:00","pubTimestamp":1739887200,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, February 18, 2025----Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT .Natera’s Fourth Quarter & Full Year 2024 Financial Results. Natera is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments  in Austin, Texas, and San Carlos, California. For more i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-report-fourth-quarter-full-140000252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CLIA","LU2065169927.USD","LU1988902786.USD","NTRA","LU0106261612.USD","LU2264538146.SGD","LU2065171311.SGD","LU1064131342.USD","LU0012050646.USD","LU2065731478.USD","LU0053671581.USD","LU2065170008.USD","LU0963586101.USD","LU2065171402.SGD","BK4139"],"gpt_icon":0},{"id":"2510372726","title":"GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System","url":"https://stock-news.laohu8.com/highlight/detail?id=2510372726","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510372726?lang=en_us&edition=fundamental","pubTime":"2025-02-12 22:00","pubTimestamp":1739368800,"startTime":"0","endTime":"0","summary":"GRAIL's GalleriTest Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience. MENLO PARK, Calif. and SECAUCUS, N.J., Feb. 12, 2025 /PRNewswire/ -- GRAIL, Inc. , a healthcare company whose mission is to detect cancer early when it can be cured, and Quest Diagnostics , a leading provider of diagnostic information services, today announced the initial phase of a program to improve provider access to GRAIL's Galleri multi-cancer early detection  test. Providers can now order the Galleri test directly from GRAIL through the Quest Diagnostics connectivity system. The Quest Diagnostics connectivity system enables providers in the United States to order and receive reports of laboratory tests electronically through Quest's Quanum laboratory portal and more than 900 electronic health record  systems. More than 500,000 providers used the Quest connectivity system last year.\"We know every minute co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/grail-quest-diagnostics-grails-galleri-140000621.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/grail-quest-diagnostics-grails-galleri-140000621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4583","BK4139","CLIA","LU1854103824.USD","BK4084","BK4217","DGX","BK4588","BK4533","GRAL","LU1854104046.USD","BK4585","BK4196","PSA","BK4567"],"gpt_icon":0},{"id":"2510593948","title":"NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2510593948","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510593948?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:00","pubTimestamp":1739188800,"startTime":"0","endTime":"0","summary":"National Comprehensive Cancer Network  Guidelines for colon and rectal cancer were updated to include ctDNA as a prognostic marker and high risk factor for recurrence. NCCN guideline for merkel cell carcinoma cites SignateraTM data and now includes positive recommendation for ctDNA monitoring in surveillance. In its updated guidelines for colon cancer1 and for rectal cancer2, NCCN now includes ctDNA as a high risk factor for recurrence in the adjuvant setting, recognizing its prognostic value. This represents a significant step forward as it’s the first time the committee has formally recognized ctDNA as being prognostic. The guidelines remain cautious about ctDNA for surveillance, as expected. The NCCN finalized these updates before data from the phase III CALGB  / SWOG 80702 study were presented at ASCO GI in January, supporting the predictive nature of Signatera in the adjuvant setting.\"These guideline changes came faster than expected given the typical timelines to be included,\" sa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nccn-strengthens-guidance-ctdna-colon-120000435.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1064131342.USD","BK4139","LU0012050646.USD","LU1988902786.USD","LU2065171311.SGD","LU2264538146.SGD","LU0106261612.USD","CLIA","LU2065731478.USD","LU2065171402.SGD","NTRA","LU2065170008.USD","LU0053671581.USD","LU2065169927.USD"],"gpt_icon":0},{"id":"2508128441","title":"Natera Announces National Commercial Coverage for its Fetal RhD NIPT","url":"https://stock-news.laohu8.com/highlight/detail?id=2508128441","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508128441?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:00","pubTimestamp":1738584000,"startTime":"0","endTime":"0","summary":"Coverage from one of the largest payors in the country expands access to fetal RhD testing for pregnant patients nationwide. AUSTIN, Texas, February 03, 2025----Natera, Inc. , a global leader in cell-free DNA  and genetic testing, today announced a new policy for commercial coverage of its cfDNA Fetal RhD noninvasive prenatal test  from one of the largest payors in the United States.Effective as of Jan. 2025, the policy notes that coverage of fetal RhD testing is available when a pregnancy may be at risk for alloimmunization, when paternal antigen typing is unavailable or heterozygous, and if a patient declines amniocentesis or it is not recommended for the pregnancy.Up to 15 percent of pregnant patients are RhD-negative1. When the maternal blood type is RhD-negative and the fetal blood type is RhD-positive, antibodies can develop  that can lead to hemolytic disease of the fetus and newborn.\"These new policies expand access to important testing that can prevent unnecessary medical trea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-announces-national-commercial-coverage-120000466.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065171402.SGD","LU1064131342.USD","LU2065170008.USD","BK4139","LU2065169927.USD","LU2065171311.SGD","CLIA","NHLD","LU2065731478.USD","LU1988902786.USD","LU0053671581.USD","LU2264538146.SGD","NTRA","LU0106261612.USD","LU0012050646.USD"],"gpt_icon":0},{"id":"2506749298","title":"Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2506749298","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506749298?lang=en_us&edition=fundamental","pubTime":"2025-01-25 23:05","pubTimestamp":1737817500,"startTime":"0","endTime":"0","summary":"Readout of ~1K patients at ASCO GI 2025 demonstrates that Signatera positive patients treated with both chemotherapy and celecoxib had a 40% improvement in overall survival versus chemotherapy alone. AUSTIN, Texas,, January 25, 2025----Natera, Inc. , a global leader in cell-free DNA and genetic testing, announced new data from the randomized, Phase III CALGB  / SWOG 80702 study. The study will be presented today, Jan. 25, 2025 as a late-breaking oral presentation at the 2025 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium  in San Francisco, CA.Signatera-positivity after surgery was predictive of a disease-free survival  and overall survival  benefit with the addition of celecoxib to adjuvant FOLFOX. The addition of celecoxib to SOC chemotherapy significantly improved DFS compared to placebo  among Signatera-positive patients with a three-year DFS of 44.1% versus 26.6%. Similar results were seen for OS . No survival benefit was seen by adding celecoxib to chem","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-announces-successful-readout-randomized-150500221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1861220207.SGD","LU0012050646.USD","LU1064131342.USD","BK4588","OS","LU0106261612.USD","LU0266512127.USD","BK4134","DFS","NTRA","LU2065170008.USD","LU1988902786.USD","LU2264538146.SGD","LU2065171311.SGD","LU0456854461.SGD","LU2065169927.USD","LU1668664300.SGD","LU0053671581.USD","LU2065171402.SGD","LU2360107671.USD","LU0106831901.USD","SOC","BK4585","LU2065731478.USD","LU1861217088.USD","CRC","BK4139","BK4166","III","BK4213","BK4097","CLIA","LU1791807156.HKD"],"gpt_icon":0},{"id":"2505739819","title":"Natera to Present New Data at the 2025 ASCO GI Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2505739819","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505739819?lang=en_us&edition=fundamental","pubTime":"2025-01-22 07:05","pubTimestamp":1737500700,"startTime":"0","endTime":"0","summary":"First set of abstracts released include Signatera data from BESPOKE CRC, the largest prospective, observational, multicenter MRD study in the U.S. to date, along with the first read-outs in early cancer detection and tissue-free MRD. Additional Signatera data will be shared at ASCO GI on Jan. 25, 2025, including a late-breaking oral presentation on the CALGB  / SWOG 80702 study. AUSTIN, Texas, January 21, 2025----Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that the first set of abstracts have been released from several studies that will be shared at the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium  taking place Jan. 23 – 25, 2025 in San Francisco, CA.Natera will also present case-control data in early cancer detection, in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-present-data-2025-asco-230500425.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065171402.SGD","LU1861220207.SGD","LU0456854461.SGD","CLIA","LU2360107671.USD","BK4588","LU2264538146.SGD","LU1668664300.SGD","PT","DFS","CRC","LU2065731478.USD","LU0053671581.USD","LU0106261612.USD","LU0012050646.USD","LU1791807156.HKD","LU1861217088.USD","LU0266512127.USD","LU2065171311.SGD","BK4585","LU1988902786.USD","LU0106831901.USD","NTRA","LU2065170008.USD","BK4139","LU2065169927.USD","BK4213","LU1064131342.USD","BK4166"],"gpt_icon":0},{"id":"2504791164","title":"Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2504791164","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504791164?lang=en_us&edition=fundamental","pubTime":"2025-01-17 22:00","pubTimestamp":1737122400,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, January 17, 2025----Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that its CEO, Steve Chapman, has been selected as one of the top healthcare technology CEOs for 2024, as determined by Healthcare Technology Report. Chapman was also named \"BioTechnology Innovator of the Year\" in 2024, in the fourth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough. These recognitions highlight Chapman’s leadership at Natera, where he has served as CEO since Jan. 2019.Chapman is a leading authority on the commercialization of genetic testing. Before his appointment as CEO in 2019, he held a number of other leadership positions at Natera including chief operating officer. Earlier in his career, he worked at Genzyme Genetics. He began his career as a researcher in the departm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-ceo-steve-chapman-recognized-140000004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0053671581.USD","HCSG","LU2065171402.SGD","BK4139","LU2065731478.USD","LU1064131342.USD","LU2065170008.USD","LU0012050646.USD","LU2065171311.SGD","NTRA","LU0106261612.USD","BK4137","LU2264538146.SGD","CLIA","LU1988902786.USD","LU2065169927.USD"],"gpt_icon":0},{"id":"2503648675","title":"Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection","url":"https://stock-news.laohu8.com/highlight/detail?id=2503648675","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503648675?lang=en_us&edition=fundamental","pubTime":"2025-01-15 20:00","pubTimestamp":1736942400,"startTime":"0","endTime":"0","summary":"Company to provide comprehensive update in a presentation delivered today at the 43rd Annual J.P. Morgan Healthcare Conference. Presentation outlines strength of existing oncology portfolio, along with pipeline of new products and data readouts. AUSTIN, Texas, January 15, 2025----Natera, Inc. , a global leader in cell-free DNA testing, will provide an update to the investment community, today, at the 43rd annual J.P. Morgan Healthcare Conference. In addition to its previously announced preliminary financial results for the fourth quarter and year ended Dec. 31, 2024, the Company will also present details on its innovation roadmap for oncology.\"Building on our strong preliminary financial results in 2024, we are poised for an exciting year with multiple potential catalysts,\" said Steve Chapman, CEO. \"Since launching the oncology business, we have focused on innovating the field of molecular residual disease testing to improve outcomes for patients. Today's announcement extends that comm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-announces-innovation-roadmap-advancements-120000132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0417517546.SGD","WGS","BK4213","LU0456854461.SGD","BK4153","LU2065731478.USD","LU2065170008.USD","BK4196","CLIA","LU0012050646.USD","BK4139","LU0256863902.USD","LU2065171402.SGD","IR","CRC","BK4588","BK4161","SG9999001440.SGD","BK4585","LU2065171311.SGD","LU0266512127.USD","AA","LU0124384867.USD","LU2264538146.SGD","NGS","NTRA","LU0256863811.USD","LU0106261612.USD","LU0053671581.USD","LU1064131342.USD","LU1988902786.USD","LU2065169927.USD","BK4179","LU1978683503.SGD"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":1,"totalSize":59}]}}